8-K Announcements
6Material company update
Feb 10, 2026·SEC
Material company update
Dec 29, 2025·SEC
Material company update
Nov 5, 2025·SEC
Dynavax Technologies Corporation(DVAX)Earnings, Financials & Key Ratios
DVAX•NASDAQ
77.5× P/E·Price updated Apr 24, 2026
AboutDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.Show more
- Revenue$277M+19.4%
- EBITDA$4M+113.2%
- Net Income$27M+527.4%
- EPS (Diluted)0.20+503.2%
- Gross Margin82.17%+4.8%
- EBITDA Margin1.42%+111.1%
- Operating Margin-1.49%+90.7%
- Net Margin9.85%+458.1%
- ROE4.48%+521.9%
DVAX Key Insights
Dynavax Technologies Corporation (DVAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 25.5%
- ✓FCF machine: 21.7% free cash flow margin
- ✓Momentum leader: RS Rating 89 (top 11%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 51.1%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DVAX Price & Volume
Dynavax Technologies Corporation (DVAX) stock price & volume — 10-year historical chart
Loading chart...
DVAX Growth Metrics
Dynavax Technologies Corporation (DVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.05%
5 Years51.08%
3 Years-14.23%
TTM26.73%
Profit CAGR
10 Years-
5 Years-
3 Years-29.13%
TTM-311.94%
EPS CAGR
10 Years-
5 Years-
3 Years-29.47%
TTM-395.34%
Return on Capital
10 Years-32.07%
5 Years8.77%
3 Years12.79%
Last Year-0.45%
DVAX Recent Earnings
Dynavax Technologies Corporation (DVAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 7/12 qtrs (64%)
Q1 2026Latest
Feb 19, 2026Metric
Actual
Est
EPS
$0.05-38.5%
$0.08
Rev
—
$82M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.21+50.0%
$0.14
Rev
$95M+18.2%
$80M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.14+16.7%
$0.12
Rev
$95M+1.5%
$94M
Q2 2025
May 6, 2025Metric
Actual
Est
EPS
$0.11-466.7%
$0.03
Rev
$68M-19.0%
$84M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 19, 2026 | $0.05vs $0.08-38.5% | —vs $82M |
| Q4 2025 | Nov 5, 2025 | $0.21vs $0.14+50.0% | $95Mvs $80M+18.2% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.12+16.7% | $95Mvs $94M+1.5% |
| Q2 2025 | May 6, 2025 | $0.11vs $0.03-466.7% | $68Mvs $84M-19.0% |
Based on last 12 quarters of dataView full earnings history →
DVAX Peer Comparison
Dynavax Technologies Corporation (DVAX) competitors in Vaccines and biodefense products — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 SIGA | 309.85M | 4.32 | 13.09 | -31.8% | 21.61% | 10.62% | 0.00 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 VXRT | 133.33M | 0.55 | 7.87 | 7.27% | 14.51% | 61.43% | 0.10 | |
 IBRX | 7.71B | 7.36 | -19.37 | 6.68% | -6.06% | |||
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 |
Compare DVAX vs Peers
Dynavax Technologies Corporation (DVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DVAX Income Statement
Dynavax Technologies Corporation (DVAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 11.04M | 327K | 8.2M | 35.22M | 46.55M | 439.44M | 722.68M | 232.28M | 277.25M | 330.51M |
Revenue Growth % | 172.67% | -97.04% | 2407.03% | 329.6% | 32.18% | 844% | 64.45% | -67.86% | 19.36% | 26.73% |
Cost of Goods Sold | 0 | 1.19M | 21.8M | 19.39M | 13.91M | 173.57M | 262.15M | 50.17M | 49.45M | 55.62M |
COGS % of Revenue | - | 365.14% | 265.87% | 55.05% | 29.88% | 39.5% | 36.27% | 21.6% | 17.83% | - |
Gross Profit | 11.04M▲ 0% | -867K▼ 107.9% | -13.6M▼ 1468.4% | 15.83M▲ 216.4% | 32.64M▲ 106.2% | 265.87M▲ 714.5% | 460.53M▲ 73.2% | 182.12M▼ 60.5% | 227.8M▲ 25.1% | 274.9M▲ 0% |
Gross Margin % | 100% | -265.14% | -165.87% | 44.95% | 70.12% | 60.5% | 63.73% | 78.4% | 82.17% | 83.17% |
Gross Profit Growth % | 172.67% | -107.85% | -1468.4% | 216.41% | 106.2% | 714.53% | 73.22% | -60.45% | 25.09% | - |
Operating Expenses | 121.75M | 93.55M | 139.72M | 150.67M | 107.86M | 131.38M | 177.01M | 219.15M | 231.92M | 264.46M |
OpEx % of Revenue | 1102.51% | 28608.26% | 1704.33% | 427.82% | 231.71% | 29.9% | 24.49% | 94.34% | 83.65% | - |
Selling, General & Admin | 37.26M | 27.37M | 64.77M | 74.99M | 79.26M | 100.16M | 131.41M | 152.95M | 170.37M | 179.71M |
SG&A % of Revenue | 337.38% | 8369.11% | 790.07% | 212.91% | 170.26% | 22.79% | 18.18% | 65.84% | 61.45% | - |
Research & Development | 84.49M | 64.99M | 74.95M | 62.33M | 28.61M | 32.23M | 46.6M | 54.89M | 61.55M | 73.78M |
R&D % of Revenue | 765.13% | 19874.01% | 914.26% | 176.98% | 61.45% | 7.33% | 6.45% | 23.63% | 22.2% | - |
Other Operating Expenses | 0 | -486K | -70K | 13.36M | 0 | -1M | -1M | 11.31M | 0 | 1000K |
Operating Income | -110.71M▲ 0% | -96M▲ 13.3% | -153.32M▼ 59.7% | -134.84M▲ 12.1% | -75.22M▲ 44.2% | 134.49M▲ 278.8% | 283.52M▲ 110.8% | -37.03M▼ 113.1% | -4.12M▲ 88.9% | 10.44M▲ 0% |
Operating Margin % | -1002.51% | -29359.33% | -1870.2% | -382.87% | -161.59% | 30.6% | 39.23% | -15.94% | -1.49% | 3.16% |
Operating Income Growth % | -5.36% | 13.28% | -59.7% | 12.05% | 44.22% | 278.79% | 110.82% | -113.06% | 88.87% | - |
EBITDA | -108.45M | -91.57M | -138.84M | -113.31M | -65.89M | 141.54M | 290.19M | -29.75M | 3.93M | 18.68M |
EBITDA Margin % | -982.07% | -28002.14% | -1693.53% | -321.74% | -141.54% | 32.21% | 40.15% | -12.81% | 1.42% | 5.65% |
EBITDA Growth % | -4.57% | 15.57% | -51.62% | 18.38% | 41.85% | 314.83% | 105.02% | -110.25% | 113.21% | 957.18% |
D&A (Non-Cash Add-back) | 2.26M | 4.44M | 14.48M | 21.53M | 9.34M | 7.06M | 6.67M | 7.28M | 8.05M | 8.24M |
EBIT | -112.44M | -95.15M | -149.56M | -135.62M | -56.18M | 88.7M | 301.03M | 2.39M | 37.65M | -33.89M |
Net Interest Income | 755K | 1.34M | -5.51M | -13.61M | -17.8M | -11.04M | 1.18M | 25.24M | 29.67M | 23.13M |
Interest Income | 755K | 1.34M | 3.83M | 3.37M | 1.26M | 140K | 7.91M | 31.99M | 36.46M | 29.54M |
Interest Expense | 0 | 0 | 9.34M | 16.98M | 19.06M | 11.18M | 6.73M | 6.76M | 6.79M | 6.41M |
Other Income/Expense | -1.74M | 851K | -5.58M | -17.76M | -18K | -56.97M | 10.78M | 32.66M | 34.98M | -51.05M |
Pretax Income | -112.44M▲ 0% | -95.15M▲ 15.4% | -158.9M▼ 67.0% | -152.6M▲ 4.0% | -75.24M▲ 50.7% | 77.52M▲ 203.0% | 294.3M▲ 279.6% | -4.37M▼ 101.5% | 30.86M▲ 806.5% | -40.61M▲ 0% |
Pretax Margin % | -1018.24% | -29099.08% | -1938.27% | -433.29% | -161.63% | 17.64% | 40.72% | -1.88% | 11.13% | -12.29% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 808K | 1.14M | 2.02M | 3.55M | 2.79M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 1.04% | 0.39% | -46.3% | 11.49% | -6.87% |
Net Income | -112.44M▲ 0% | -95.15M▲ 15.4% | -158.9M▼ 67.0% | -152.6M▲ 4.0% | -75.24M▲ 50.7% | 76.71M▲ 202.0% | 293.16M▲ 282.1% | -6.39M▼ 102.2% | 27.31M▲ 527.4% | -43.4M▲ 0% |
Net Margin % | -1018.24% | -29099.08% | -1938.27% | -433.29% | -161.63% | 17.46% | 40.56% | -2.75% | 9.85% | -13.13% |
Net Income Growth % | -5.29% | 15.38% | -66.99% | 3.96% | 50.69% | 201.96% | 282.15% | -102.18% | 527.44% | -311.94% |
Net Income (Continuing) | -112.44M | -95.15M | -158.9M | -152.6M | -75.24M | 76.71M | 293.16M | -6.39M | 27.31M | -43.4M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.92▲ 0% | -1.81▲ 38.0% | -2.55▼ 40.9% | -2.10▲ 17.6% | -0.78▲ 62.9% | 0.57▲ 173.1% | 1.97▲ 245.6% | -0.05▼ 102.5% | 0.20▲ 503.2% | -0.32▲ 0% |
EPS Growth % | 10.15% | 38.01% | -40.88% | 17.65% | 62.86% | 173.08% | 245.61% | -102.52% | 503.23% | -395.34% |
EPS (Basic) | -2.92 | -1.81 | -2.55 | -2.10 | -0.75 | 0.62 | 2.32 | -0.05 | 0.21 | - |
Diluted Shares Outstanding | 38.51M | 52.61M | 62.36M | 72.02M | 100.75M | 133.01M | 150.8M | 128.73M | 133.34M | 136.47M |
Basic Shares Outstanding | 38.51M | 52.61M | 62.36M | 72.02M | 100.75M | 116.26M | 126.4M | 128.73M | 130.05M | 117.31M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DVAX Balance Sheet
Dynavax Technologies Corporation (DVAX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 81.42M | 191.85M | 164.56M | 208.65M | 290.01M | 972.52M | 916.99M | 859.12M | 848.94M | 814.33M |
Cash & Short-Term Investments | 81.42M | 191.85M | 145.54M | 151.06M | 165.04M | 545.95M | 624.39M | 742.3M | 713.83M | 647.82M |
Cash Only | 24.29M | 26.58M | 49.35M | 39.88M | 32.07M | 436.19M | 202M | 150.28M | 95.88M | 160.25M |
Short-Term Investments | 57.13M | 165.27M | 96.19M | 111.17M | 132.96M | 109.76M | 422.39M | 592.02M | 617.95M | 487.57M |
Accounts Receivable | 1.34M | 854K | 3.7M | 8.89M | 22.66M | 131.82M | 147.51M | 44.53M | 46.91M | 73.32M |
Days Sales Outstanding | 44.36 | 953.24 | 164.91 | 92.09 | 177.68 | 109.49 | 74.5 | 69.98 | 61.75 | 69.06 |
Inventory | -8.18M | 312K | 19.02M | 41.33M | 63.69M | 61.34M | 59.45M | 53.29M | 70.05M | 73.29M |
Days Inventory Outstanding | - | 95.38 | 318.55 | 778.08 | 1.67K | 128.98 | 82.77 | 387.72 | 517.13 | 481.43 |
Other Current Assets | 6.84M | 1.31M | 6.1M | 0 | 0 | 73.76M | 85.63M | 19M | 18.15M | 19.91M |
Total Non-Current Assets | 28.27M | 26.93M | 46.33M | 70.42M | 63.26M | 66.73M | 68.86M | 137.98M | 137.31M | 132.18M |
Property, Plant & Equipment | 17.17M | 16.62M | 17.06M | 62.27M | 57.15M | 60.98M | 63.34M | 61.58M | 60.61M | 65.76M |
Fixed Asset Turnover | 0.64x | 0.02x | 0.48x | 0.57x | 0.81x | 7.21x | 11.41x | 3.77x | 4.57x | 5.16x |
Goodwill | 1.97M | 2.24M | 2.14M | 2.08M | 2.3M | 2.13M | 2.01M | 2.07M | 1.95M | 2.2M |
Intangible Assets | 0 | 0 | 11.72M | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 602K | 629K | 619K | 0 | 0 | 0 | 0 | 0 | 71.58M | 305K |
Other Non-Current Assets | 9.12M | 8.07M | 15.4M | 3.56M | 3.81M | 3.62M | 3.52M | 74.33M | 3.18M | 64.22M |
Total Assets | 109.68M▲ 0% | 218.78M▲ 99.5% | 210.88M▼ 3.6% | 279.07M▲ 32.3% | 353.27M▲ 26.6% | 1.04B▲ 194.2% | 985.85M▼ 5.1% | 997.1M▲ 1.1% | 986.26M▼ 1.1% | 946.51M▲ 0% |
Asset Turnover | 0.10x | 0.00x | 0.04x | 0.13x | 0.13x | 0.42x | 0.73x | 0.23x | 0.28x | 0.35x |
Asset Growth % | -49.37% | 99.48% | -3.61% | 32.33% | 26.59% | 194.18% | -5.14% | 1.14% | -1.09% | -25.71% |
Total Current Liabilities | 20.04M | 18.59M | 38.03M | 53.05M | 77.41M | 556.4M | 150.07M | 62.2M | 78.63M | 106.84M |
Accounts Payable | 3.8M | 4.54M | 5.28M | 9.28M | 3.31M | 2.6M | 3.21M | 5.25M | 9.06M | 3.95M |
Days Payables Outstanding | - | 1.39K | 88.39 | 174.66 | 86.91 | 5.47 | 4.47 | 38.16 | 66.89 | 32.88 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.17M | 40.07M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 38.21M | 349.86M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 24.7M | 24.85M | 10.74M | 18.03M | 0 | 24K | 22K | 4.23M |
Current Ratio | 4.06x | 10.32x | 4.33x | 3.93x | 3.75x | 1.75x | 6.11x | 13.81x | 10.80x | 7.62x |
Quick Ratio | 4.47x | 10.30x | 3.83x | 3.15x | 2.92x | 1.64x | 5.71x | 12.96x | 9.91x | 6.94x |
Cash Conversion Cycle | - | -338.93 | 395.07 | 695.51 | 1.76K | 233 | 152.8 | 419.54 | 512 | 517.61 |
Total Non-Current Liabilities | 20.48M | 19.24M | 109.79M | 217.73M | 217.17M | 260.47M | 254.76M | 312.83M | 310.82M | 305.53M |
Long-Term Debt | 0 | 0 | 100.87M | 178.6M | 179.81M | 220.49M | 221.58M | 222.7M | 223.85M | 220.97M |
Capital Lease Obligations | 0 | 0 | 0 | 37.84M | 34.79M | 34.32M | 32.8M | 29.72M | 26.39M | 100.62M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20.48M | 643K | 8.91M | 1.28M | 2.57M | 5.66M | 384K | 60.41M | 60.58M | 60.58M |
Total Liabilities | 20.48M | 19.24M | 147.82M | 270.78M | 294.58M | 816.87M | 404.84M | 375.02M | 389.46M | 412.37M |
Total Debt | 0 | 0 | 100.87M | 216.45M | 217.85M | 257.38M | 258.01M | 256.91M | 254.42M | 285.02M |
Net Debt | -24.29M | -26.58M | 51.52M | 176.56M | 185.77M | -178.81M | 56.01M | 106.64M | 158.53M | 124.78M |
Debt / Equity | - | - | 1.60x | 26.11x | 3.71x | 1.16x | 0.44x | 0.41x | 0.43x | 0.53x |
Debt / EBITDA | - | - | - | - | - | 1.82x | 0.89x | - | 64.74x | 15.26x |
Net Debt / EBITDA | - | - | - | - | - | -1.26x | 0.19x | - | 40.34x | 6.68x |
Interest Coverage | - | - | -16.42x | -7.94x | -3.95x | 12.03x | 42.12x | -5.48x | -0.61x | -5.28x |
Total Equity | 89.2M▲ 0% | 199.55M▲ 123.7% | 63.06M▼ 68.4% | 8.29M▼ 86.9% | 58.69M▲ 608.0% | 222.37M▲ 278.9% | 581.01M▲ 161.3% | 622.07M▲ 7.1% | 596.8M▼ 4.1% | 534.14M▲ 0% |
Equity Growth % | -52.32% | 123.71% | -68.4% | -86.85% | 608% | 278.88% | 161.28% | 7.07% | -4.06% | -62.96% |
Book Value per Share | 2.32 | 3.79 | 1.01 | 0.12 | 0.58 | 1.67 | 3.85 | 4.83 | 4.48 | 3.91 |
Total Shareholders' Equity | 89.2M | 199.55M | 63.06M | 8.29M | 58.69M | 222.37M | 581.01M | 622.07M | 596.8M | 534.14M |
Common Stock | 39K | 62K | 63K | 84K | 110K | 123K | 128K | 130K | 125K | 117K |
Retained Earnings | -812.17M | -907.33M | -1.07B | -1.22B | -1.29B | -1.22B | -924.2M | -930.58M | -903.27M | -953.73M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3.62M | -881K | -2.02M | -2.39M | 273K | -2.27M | -5.44M | -2.11M | -4.72M | 800K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DVAX Cash Flow Statement
Dynavax Technologies Corporation (DVAX) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -107.05M | -77.52M | -131.3M | -121.25M | -92.25M | 335.53M | 62.72M | 100.56M | 66.51M | 90.63M |
Operating CF Margin % | -969.4% | -23705.81% | -1601.62% | -344.28% | -198.17% | 76.35% | 8.68% | 43.29% | 23.99% | - |
Operating CF Growth % | -15.66% | 27.59% | -69.38% | 7.65% | 23.92% | 463.71% | -81.31% | 60.35% | -33.86% | 459.83% |
Net Income | -112.44M | -95.15M | -158.9M | -152.6M | -75.24M | 76.71M | 293.16M | -6.39M | 27.31M | -43.4M |
Depreciation & Amortization | 2.26M | 4.44M | 14.48M | 21.53M | 9.34M | 7.06M | 6.67M | 7.28M | 8.05M | 8.24M |
Stock-Based Compensation | 14.13M | 14.92M | 23.48M | 25.46M | 13.48M | 21.29M | 32.91M | 42.59M | 52.62M | 52.83M |
Deferred Taxes | 1.13M | -203K | -1.46M | 6.06M | 0 | 0 | 61.77M | -5.24M | 0 | 0 |
Other Non-Cash Items | 602K | -209K | 2.75M | 11.97M | -6.92M | 58.25M | -33.38M | 1.12M | -5.43M | 90.65M |
Working Capital Changes | -12.72M | -1.31M | -11.66M | -33.67M | -32.91M | 172.22M | -298.42M | 61.21M | -16.04M | -17.68M |
Change in Receivables | 52K | 52K | 7.34M | -17.84M | -13.78M | -109.16M | -15.7M | 43.27M | -2.37M | 1.96M |
Change in Inventory | -11.2M | -312K | -18.71M | -22.31M | -22.36M | -234K | -32.4M | 3.91M | -19.91M | -16.41M |
Change in Payables | 1.18M | -1.92M | 3.42M | 4.85M | -3.45M | -767K | 691K | 1.95M | 3.9M | -3.27M |
Cash from Investing | 86.25M | -108.7M | 55.47M | -42.78M | -26.53M | 14.22M | -316M | -153.93M | -18.04M | 152.39M |
Capital Expenditures | -7.76M | -669K | -15.19M | -29.4M | -4.07M | -9.48M | -7.14M | -4.1M | -6.35M | -10.1M |
CapEx % of Revenue | 70.24% | 204.59% | 185.25% | 83.48% | 8.75% | 2.16% | 0.99% | 1.77% | 2.29% | 3.05% |
Acquisitions | 0 | 0 | 11M | 7M | 0 | 0 | 1M | 1M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -11M | -7M | -149K | 1M | 0 | 0 | 0 | 0 |
Cash from Financing | 531K | 187.84M | 99.07M | 154.35M | 109.5M | 55.78M | 19.52M | 1.39M | -102.02M | -202.74M |
Debt Issued (Net) | 0 | 0 | 99M | 74.25M | 0 | 29.63M | 0 | 0 | 0 | -41.79M |
Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | -3.57M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -84K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -100M | -201.21M |
Other Financing | 531K | 1.91M | 71K | 567K | 961K | -2.01M | 1.43M | -4.97M | -2.02M | 40.18M |
Net Change in Cash | -20.52M▲ 0% | 2.29M▲ 111.2% | 22.75M▲ 891.5% | -9.87M▼ 143.4% | -7.79M▲ 21.0% | 404.1M▲ 5287.4% | -234.2M▼ 158.0% | -51.66M▲ 77.9% | -54.4M▼ 5.3% | 40.95M▲ 0% |
Free Cash Flow | -114.81M▲ 0% | -78.19M▲ 31.9% | -146.49M▼ 87.4% | -150.65M▼ 2.8% | -103.32M▲ 31.4% | 326.05M▲ 415.6% | 55.58M▼ 83.0% | 96.46M▲ 73.6% | 60.16M▼ 37.6% | 80.54M▲ 0% |
FCF Margin % | -1039.64% | -23910.4% | -1786.87% | -427.76% | -221.96% | 74.2% | 7.69% | 41.53% | 21.7% | 24.37% |
FCF Growth % | -15.35% | 31.9% | -87.36% | -2.84% | 31.42% | 415.56% | -82.95% | 73.56% | -37.63% | 255.26% |
FCF per Share | -2.98 | -1.49 | -2.35 | -2.09 | -1.03 | 2.45 | 0.37 | 0.75 | 0.45 | 0.59 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.81x | 0.83x | 0.79x | 1.23x | 4.37x | 0.21x | -15.74x | 2.44x | -1.86x |
Interest Paid | 0 | 0 | 0 | 0 | 16.54M | 9.81M | 5.64M | 5.64M | 5.64M | 2.02M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 1.31M | 2.21M | 2.01M | 4.58M | 2.6M |
DVAX Key Ratios
Dynavax Technologies Corporation (DVAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -81.4% | -65.91% | -121.01% | -427.72% | -224.65% | 54.59% | 72.98% | -1.06% | 4.48% | -8.13% |
Return on Invested Capital (ROIC) | -80.15% | -60.54% | -79.98% | -67.55% | -26.28% | 70.04% | 62.49% | -4.07% | -0.42% | 1.09% |
Gross Margin | 100% | -265.14% | -165.87% | 44.95% | 70.12% | 60.5% | 63.73% | 78.4% | 82.17% | 83.17% |
Net Margin | -1018.24% | -29099.08% | -1938.27% | -433.29% | -161.63% | 17.46% | 40.56% | -2.75% | 9.85% | -13.13% |
Debt / Equity | - | - | 1.60x | 26.11x | 3.71x | 1.16x | 0.44x | 0.41x | 0.43x | 0.53x |
Interest Coverage | - | - | -16.42x | -7.94x | -3.95x | 12.03x | 42.12x | -5.48x | -0.61x | -5.28x |
FCF Conversion | 0.95x | 0.81x | 0.83x | 0.79x | 1.23x | 4.37x | 0.21x | -15.74x | 2.44x | -1.86x |
Revenue Growth | 172.67% | -97.04% | 2407.03% | 329.6% | 32.18% | 844% | 64.45% | -67.86% | 19.36% | 26.73% |
Related:DVAX Dividend History·DVAX Revenue History·DVAX Price History·DVAX P/E History·DVAX Financial Ratios·DVAX Institutional Holders
DVAX SEC Filings & Documents
Dynavax Technologies Corporation (DVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
DVAX Frequently Asked Questions
Dynavax Technologies Corporation (DVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Dynavax Technologies Corporation (DVAX) reported $330.5M in revenue for fiscal year 2024. This represents a 23061% increase from $1.4M in 2002.
Dynavax Technologies Corporation (DVAX) grew revenue by 19.4% over the past year. This is strong growth.
Dynavax Technologies Corporation (DVAX) reported a net loss of $43.4M for fiscal year 2024.
Dividend & Returns
Dynavax Technologies Corporation (DVAX) has a return on equity (ROE) of 4.5%. This is below average, suggesting room for improvement.
Dynavax Technologies Corporation (DVAX) generated $80.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.